
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
An advanced clinical medical oncology guide on managing aggressive Triple-Negative Breast Cancer (ER-/PR-/HER2-), detailing neoadjuvant KEYNOTE-522 immunotherapy with Pembrolizumab, carboplatin-paclitaxel combinations, pathological complete response (pCR) benchmarks, and BRCA/gBRCA PARP maintenance.
CRITICAL CLINICAL RED FLAG: Any rapidly enlarging, painless, firm breast mass with skin tethering, nipple retraction, or enlarged axillary lymph nodes in younger females requires prompt triple assessment (bilateral digital mammography, ultrasound, and core needle biopsy with ER, PR, HER2, and Ki-67 immunohistochemistry).
TNBC accounts for roughly 15–20% of all breast carcinomas but disproportionately affects younger women. Lacking Estrogen (ER), Progesterone (PR), and HER2/neu amplification, TNBC does not respond to hormonal endocrine therapy or trastuzumab. Neoadjuvant systemic therapy is therefore the foundational frontline treatment.
High Proliferation (Ki-67 >50%): Drives rapid clinical enlargement but simultaneously confers heightened sensitivity to DNA-damaging cytotoxic agents.
BRCA1/2 Mutation Association: Up to 20% of TNBC patients harbor germline BRCA mutations, exhibiting homologous recombination deficiency (HRD).
Immunogenic Microenvironment: Characterized by dense Tumor-Infiltrating Lymphocytes (TILs) and elevated PD-L1 expression.
The phase III KEYNOTE-522 landmark trial established the global standard of care for Stage II/III TNBC:
Neoadjuvant Phase: 4 cycles of Pembrolizumab (200 mg q3w) combined with Paclitaxel + Carboplatin, followed by 4 cycles of Pembrolizumab + Doxorubicin/Cyclophosphamide (AC).
Pathological Complete Response (pCR = ypT0/is ypN0): Increased pCR rates from 51.2% to 64.8%, which correlates with an 88% reduction in distant recurrence risk.
Adjuvant Phase: Completion of 9 cycles of single-agent Pembrolizumab post-surgery.
"Achieving pathological Complete Response (pCR) through neoadjuvant immunotherapy fundamentally resets the biological trajectory of TNBC, translating into long-term cure rates." — Dr. Neha Gupta

If residual invasive cancer remains in the surgical specimen (non-pCR), treatment is tailored based on genomic status: 1) Germline BRCA-mutated patients receive oral Olaparib (OlympiA trial) for 1 year; 2) BRCA wild-type patients receive adjuvant oral Capecitabine (CREATE-X trial) for 6 to 8 cycles.
CLINICAL CAUTION: Fine Needle Aspiration Cytology (FNAC) is strictly inadequate for breast masses; true-cut core needle biopsy is mandatory to obtain receptor status and architecture.
Marking the initial tumor bed and biopsy-proven positive axillary lymph nodes with titanium clips enables Targeted Axillary Dissection (TAD) post-chemotherapy, avoiding full axillary clearance and secondary lymphedema.
1. Pembrolizumab for Early Triple-Negative Breast Cancer (KEYNOTE-522) — New England Journal of Medicine (NEJM), 2022; 386: 556-567.
2. Adjuvant Olaparib for Germline BRCA-Mutated Breast Cancer (OlympiA Trial) — NEJM, 2021; 384: 2394-2405.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica — Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.